Use of Demineralised Bone Matrix (DBX) in Osteochondritis Dissecans (OCD)

Inclusion Criteria: * Males or females, age between 18 years and 65 years * Females of childbearing potential must have a negative serum or urine pregnancy test at the time of inclusion * Females of childbearing potential must be willing to use effective means of birth control for at least 1 year post surgery. Medically acceptable contraceptives include: 1. Surgical sterilisation 2. Approved hormonal contraceptives 3. Barriers methods combined with a spermicide 4. An intrauterine device 5. Abstinence alone is not considered an acceptable method of contraception * Late stage Osteochondritis Dissecans (ICD-10 code M93.2) of the knee classified as stage III or IV (Anderson MRI classification) * Mature skeleton * Written informed consent prior to any study specific procedures (except the procedures necessary to determine eligibility) * Ability and willingness to comply with all study specific procedures, including attending all follow-up visits up to 12 months postoperative and completing questionnaires in a local language Exclusion Criteria: * More than 1 knee affected * Patients who can be treated with conservative treatment alone, unless there is evidence of at least 6 months failed previous treatment * Systemic disease including AIDS, HIV, Hepatitis or any other disease that would prevent normal organ and marrow function. * Patients undergoing systemic cortisone treatment or immunosuppressive therapy (e.g. avascular necrosis) * Patients undergoing active cancer therapy (chemotherapy, radiation treatment). * History of alcohol abuse or illegal drug use. * Participation in any other device or drug trial within 3 months prior to the inclusion in the study * Presence of at least one contraindication for DBX® Putty